Expert Perspectives on Biosimilar Agents

In this video module, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.
Andrew M. Evens, DO, MSc, FACP
Jonathan Kay, MD
Alan C. Moss, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: November 16, 2017 Expiration: November 15, 2018
Multimedia Expert Perspectives on Biosimilar Agents
This program is divided into four segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Part 1: Fundamentals (48 mins)
Review the fundamentals of biosimilars.
Launch Part 1: Fundamentals (48 mins)
Part 2: Inflammatory Diseases (12 mins)
Explore specific questions about biosimilars in inflammatory diseases.
Launch Part 2: Inflammatory Diseases (12 mins)
Part 3: Oncology (11 mins)
Explore specific questions about biosimilars in oncology.
Launch Part 3: Oncology (11 mins)
Part 4: Challenges (5 mins)
Address the greatest challenges for biosimilars.
Launch Part 4: Challenges (5 mins)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain the similarities and differences between biosimilars, reference biologics, and small molecule generics
  • Compare available safety and efficacy data for available biosimilars and reference biologics and the potential impact of interchangeability, extrapolation of indications, and substitution on dose/response, adverse events, and clinical outcomes
  • Summarize the key steps outlined by the FDA to demonstrate biosimilarity between a biosimilar and its reference biologic
  • Compare the regulatory approval pathway between a small molecule generic, reference biologic and a biosimilar

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Andrew M. Evens, DO, MSc, FACP

Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Andrew M. Evens, DO, MSc, FACP, has disclosed that he has received consulting fees from Seattle Genetics and Takeda, fees for non-CME/CE services from Celgene, and funds for research support from Seattle Genetics and Takeda.

Jonathan Kay, MD

Professor of Medicine and Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Jonathan Kay, MD, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Bristol‐Myers Squibb, Janssen, Lilly, Merck, Pfizer, Roche, Samsung Bioepis, Sandoz, and UCB and funds for research support paid to his institution from AbbVie, Genentech, Lilly, Pfizer, and UCB.

Alan C. Moss, MD

Associate Professor of Medicine
Department of Gastroenterology
Harvard Medical School
Boston, Massachusetts

Alan C. Moss, MD, has disclosed that he has received consulting fees from Boehringer Ingelheim, Gilead Sciences, Janssen, Pfizer, and Seres.

Staff

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists, dermatologists, gastroenterologists, oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals interested in biosimilars.

Goal

The goal of this multidisciplinary activity is to provide clinicians in the most relevant specialties—rheumatology, dermatology, gastroenterology, and oncology—with both broad and specialty-specific perspectives on biosimilars.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 16, 2017, through November 15, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

A short slideset from Clinical Care Options covering key clinical insights for the current management of HR+/HER2- advanced breast cancer.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: July 1, 2020

Slides from Neelima Denduluri, MD, FASCO: HER2-targeted TKIs and antibody-drug conjugates for HER2-positive metastatic breast cancer, from CCO

Neelima Denduluri, MD, FASCO Released: June 30, 2020

John L. Marshall, MD discusses key data in GI malignancies from ASCO 2020 and optimizing therapeutic benefit through management of cancer cachexia

John L. Marshall, MD Released: June 30, 2020

Slides from Lee Schwartzberg, MD, FACP: Optimal treatment and management of toxicities for HER2-positive early-stage breast cancer, from CCO

Lee Schwartzberg, MD, FACP Released: June 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?